Page last updated: 2024-11-12

deoxyarbutin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-((tetrahydro-2H-pyran-2-yl)oxy)phenol: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11745519
CHEMBL ID4303145
SCHEMBL ID222919
MeSH IDM0491087

Synonyms (41)

Synonym
4-(oxan-2-yloxy)phenol
deoxyarbutin ,
53936-56-4
4-((tetrahydro-2h-pyran-2-yl)oxy)phenol
AKOS015919608
S4132
FT-0686550
phenol, 4-((tetrahydro-2h-pyran-2-yl)oxy)-
4-hydroxyphenyl tetrahydropyranyl ether
rg969by5en ,
4-(tetrahydro-2h-pyran-2-yloxy)phenol
4-((2-tetrahydropyranyl)oxy)phenol
tetrahydropyranyloxy phenol
tetrahydropyranyloxy phenol [inci]
(+/-)-tetrahydropyranyloxy phenol
tetrahydropyranyloxy phenol, (+/-)-
girlite da 100
unii-rg969by5en
SCHEMBL222919
HY-B1461
CS-5188
GFBCWCDNXDKFRH-UHFFFAOYSA-N
AC-23368
AB01566911_01
phenol, 4-[(tetrahydro-2h-pyran-2-yl)oxy]-
mfcd09970981
HMS3652A20
SW219682-1
4-(tetrahydro-pyran-2-yloxy)-phenol
SY102928
4-[(2-tetrahydropyranyl)oxy]phenol
d-arbutin
AS-18645
4-[(oxan-2-yl)oxy]phenol
DTXSID10968728
CCG-266537
CHEMBL4303145
Q27288101
NCGC00386258-01
A847928
4-(tetrahydro-2h-pyran-2-yloxy)phenol; 4-hydroxyphenyl tetrahydropyranyl ether; 4-[(2-tetrahydropyranyl)oxy]phenol

Research Excerpts

Overview

DeoxyArbutin (dA) is a tyrosinase inhibitor that has effective skin-lightening activity. It has no obvious cytotoxicity toward melanocytes.

ExcerptReferenceRelevance
"DeoxyArbutin (dA) is a tyrosinase inhibitor that has effective skin-lightening activity and has no obvious cytotoxicity toward melanocytes. "( Using a Cellular System to Directly Assess the Effects of Cosmetic Microemulsion Encapsulated DeoxyArbutin.
Chang, NF; Huang, WH; Lin, CC; Tsai, FJ; Zheng, YM, 2021
)
2.28

Effects

ExcerptReferenceRelevance
"Deoxyarbutin has been characterized with: [Formula: see text] = 1.95 ± 0.06 s-1 and [Formula: see text] = 33 ± 4 μM."( Structural and kinetic considerations on the catalysis of deoxyarbutin by tyrosinase.
Berna, J; Garcia-Canovas, F; Garcia-Jimenez, A; Garcia-Ruiz, PA; Rodriguez-Lopez, JN; Saura-Sanmartin, A; Teruel-Puche, JA, 2017
)
1.42

Toxicity

Deoxyarbutin exerts potent tyrosinase inhibition and lessened cytotoxicity. It may serve as an effective and safe alternative to hydroquinone for use in skin whitening.

ExcerptReferenceRelevance
"Deoxyarbutin exerts potent tyrosinase inhibition, lessened cytotoxicity, and certain antioxidation potential, may serve as an effective and safe alternative to hydroquinone for use in skin whitening."( Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation: Biosafety as skin whitening agents.
Ding, SF; Hu, ZM; Lei, TC; Xu, SZ; Zhou, Q, 2009
)
1.8
"Although on the basis of the provided scientific data the use of deoxyarbutin as such can be considered safe for consumers in cosmetic products in a concentration up to 3% in face creams, hydroquinone will be formed at levels which raise concerns with regard to the safety of such products during life-cycle of the product (e."( Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on the safety of the use of deoxyarbutin in cosmetic products.
Degen, GH, 2016
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's10 (62.50)24.3611
2020's3 (18.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.21 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index51.95 (26.88)
Search Engine Supply Index3.93 (0.95)

This Compound (26.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]